

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Date: 31 Jan 2024

Ref. No. ANG/23-24/BSE-149

To

Department of Corporate Services
BSE Limited
P.J. Towers, Dalal Street
Mumbai - 400001.

Ref.: Scrip Code – 540694

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations')

Dear Sir/Madam,

In reference to our disclosure dated 14.08.2021 about the Assets Purchase Agreement with Ind-swift Ltd wherein the Company had agreed to acquire two formulation units of Ind-Swift Ltd (Unit III & IV) located at Village Malku Majra Tehsil Nalagarh Baddi (H.P.) for a consideration of Rs. 60 Cr. (Rupees Sixty Crores) payable by internal accrual & bank funding on deferred payment basis up to 30-Jun-2024.

With respect to the above, we inform you that ANG Lifesciences and Ind Swift Ltd entered into an agreement to amend the previous Assets Purchase Agreement (14.08.2021).

In pursuant to amended agreement, the Board of ANG has decided to acquire only Unit III of Ind-Swift Ltd for a consideration of Rs. 43.00 Crs. (Rupees Forty-Three Crores) which is already paid to Ind-Swift Ltd. Further the Registration and other formalities would be done in due course of time and shall be intimate you accordingly.

The reason for not acquiring the Unit IV of Ind- swift Ltd is that the Company wants to sustain its liquidity without raising any debt. However the Unit IV of Ind- swift Ltd was unused since Oct-2022.

We request you to kindly take the above on record.

Thanking You
Yours' faithfully

For ANG Lifesciences India Limited


Renu Kaur
Company Secretary



Renu Kaur

Digitally signed by Renu Kaur
DN: cn=Renu Kaur, o=ANG Lifesciences India Limited, email=Renu.Kaur@anglifesciences.com, c=IN
Date: 2024.01.31 10:58:58 +05'30'